Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 11/20 | 0.38 |
| ▸ | HTR2C | P28335 | 5/20 | 0.37 |
| ▸ | HTR2A | P28223 | 2/20 | 0.37 |
| ▸ | HTR7 | P34969 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HTR1B | P28222 | 1/20 | 0.37 |
| ▸ | HTR3A | P46098 | 1/20 | 0.37 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.36 |
| ▸ | CDK9 | P50750 | 2/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.35 |
| ▸ | ACLY | P53396 | 1/20 | 0.34 |
| ▸ | QDPR | P09417 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31701945 | 0.86 | HTR6 (0.40) | HTR6HTR2CHTR2AHTR7MAPT | |
| SCHEMBL31700599 | 0.86 | HTR6 (0.40) | HTR6HTR2CHTR2AHTR7MAPT | |
| SCHEMBL31702256 | 0.82 | ACLY (0.36) | HTR6HTR2CHTR2AHTR7MAPT | |
| SCHEMBL31700577 | 0.79 | HTR6 (0.39) | HTR6HTR2CHTR2AHTR7MAPT | |
| SCHEMBL31700434 | 0.78 | HTR2C (0.42) | HTR6HTR2CHTR2AHTR7MAPT | |
| SCHEMBL31700646 | 0.78 | CCNT1 (0.48) | HTR6HTR2CCCNT1CDK9QDPR | |
| SCHEMBL31700559 | 0.76 | CCNT1 (0.40) | HTR6HTR2CHTR2AHTR7CCNT1 | |
| SCHEMBL24670316 | 0.73 | SIGMAR1 (0.42) | HTR6HTR2CHTR2AHTR7MAPT | |
| SCHEMBL31701454 | 0.73 | CCNT1 (0.41) | HTR6HTR2CHTR2AHTR7CCNT1 | |
| SCHEMBL29803435 | 0.71 | MAPKAPK2 (0.47) | HTR2CMAPTCCNT1CDK9SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260014147-A1 | STAT6 DEGRADERS | GILEAD SCIENCES INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-20260001893-A1 | SMALL MOLECULE MODULATORS OF STAT6 | GILEAD SCIENCES INC (US) | 2026-01-01 | — | — | US | disclosed |
| US-20250340551-A1 | SMALL MOLECULE MODULATORS OF STAT6 | GILEAD SCIENCES INC (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250325677-A1 | STAT6 DEGRADERS | GILEAD SCIENCES INC (US) | 2025-10-23 | — | — | US | disclosed |
| US-20250320205-A1 | STAT6 DEGRADERS | GILEAD SCIENCES INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-20250320206-A1 | STAT6 DEGRADERS | GILEAD SCIENCES INC (US) | 2025-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250325677-A1 | STAT6 DEGRADERS | STAT6, STAT5B, STAT1 | HTR6 1343/4885HTR2C 2791/4885HTR2A 2011/4885 |
| US-20250340551-A1 | SMALL MOLECULE MODULATORS OF STAT6 | STAT6, STAT1, STAT5B | HTR6 2295/4885HTR2C 4066/4885HTR2A 3313/4885 |
| US-20260001893-A1 | SMALL MOLECULE MODULATORS OF STAT6 | STAT6, NCOR1, NCOR2 | HTR6 1678/4885HTR2C 1604/4885HTR2A 2731/4885 |
| US-20250320205-A1 | STAT6 DEGRADERS | STAT6, STAT1, STAT5B | HTR6 1697/4885HTR2C 3053/4885HTR2A 2309/4885 |
| US-20260014147-A1 | STAT6 DEGRADERS | STAT6, NCOR1, CBR1 | HTR6 830/4885HTR2C 650/4885HTR2A 1315/4885 |
| US-20250320206-A1 | STAT6 DEGRADERS | STAT6, STAT5B, STAT1 | HTR6 1343/4885HTR2C 2791/4885HTR2A 2011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.